Provivi, Inc. ("Provivi"), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to announce a $10M investment by the Bill & Melinda Gates Foundation ("the foundation"). This amount adds to Provivi's recently announced $45.5M C2 fundraising round.
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health
DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ -- Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health. The new capital will be used to help the company continue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.
Crop Enhancement Announces Commercial Launch of Biological Crop Protection Solution in Indonesia
Crop Enhancement, a maker of sustainable crop protection products, today announced the commercial launch of its CropCoat® solution after conducting a successful pilot project with Cargill cocoa growers in Indonesia. Growers and producers are now able to purchase Crop Enhancement's CropCoat® solution to effectively meet sustainability goals and diminish the use of chemical pesticides without negatively impacting production.
Crop Enhancement's solution takes a different approach than traditional chemical pesticides. Rather than trying to deter pests with harsh chemicals, CropCoat® coats crops to camouflage them and mitigate damage from insects, and disease. In the latest Indonesia trial conducted by Cargill's NGO partner Swisscontact with a select group of 30 cocoa farmers, CropCoat® technology has been shown to boost cocoa yields by 33% and increase grower net income by 21%.
PIVOT BIO OFFERS N-PRODUCING MICROBE FOR GRAIN SORGHUM
Grain sorghum prices are fetching a premium, and High Plains farmers may turn to that crop as an alternative to dryland corn production in 2021.
A new microbial product from Pivot Bio could help them maximize nitrogen efficiency if they do.
Pivot Bio Return is a nitrogen-producing microbe which, applied in-furrow during planting, attaches to sorghum plant roots, taking nitrogen from the air and turning it into ammonia, continually feeding nitrogen to the plant throughout the growing season.
Provivi, Inc. ("Provivi"), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to inform the completion of a $45.5M financing round. Vivo Capital, a Palo Alto based investment fund, led the round. Returning shareholders, including Kairos Ventures, Temasek, Pontifax AgTech, Tybourne Capital, Lanx Capital, and Spruce Capital, also participated in the financing.
"The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico," said Dr. Pedro Coelho, Co-Founder and CEO of Provivi. "The funds will help accelerate our recently launched fall armyworm pheromone product in Mexico, Provivi-FAWTM, and prepare for further commercial launches of products in 2021."
Provivi® Inc ("Provivi"), an emerging crop protection company using pheromones to protect crops from major damaging insects, is proud to announce the launch in México of "Provivi FAWTM" mating disruption dispenser for the control of Fall Armyworm (Spodoptera frugiperda) in corn.
"Our launch of Provivi FAWTM marks the beginning of a new era of effective, affordable, and environmentally benign protection against Fall Armyworm. This will benefit farmers not only in México but several other countries across the world, where we are currently developing and registering the product," said Pedro Coelho, CEO & Co-Founder at Provivi.
GreenLight Biosciences Receives $3.3 Million Grant to Develop Sickle Cell Disease Cure Using mRNA Gene Therapy
GreenLight Biosciences has received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges. The funding will support GreenLight’s research and testing of affordable therapies using the company’s novel messenger RNA (mRNA) approach to gene editing. mRNA technology is already being used to develop vaccine candidates for infectious diseases, including the COVID-19 pandemic.
Provivi announces regulatory approval of Pherogen SPOFR Dispenser in México
Provivi® Inc, ("Provivi") an emerging biotechnology company using pheromones to protect crops from major damaging insects, today announced the first regulatory approval in Mexico of its Pherogen™ Dispenser SpoFr ("Pherogen™") mating disruption dispenser for the control of Fall Armyworm (Spodoptera frugiperda) in corn.
The approval to commercialize Pherogen™ by the regulatory authority COFEPRIS sets a milestone in pest control in Mexico. Provivi is now able to introduce a preventative, selective, and non-toxic tool as the new foundation of Integrated Pest Management in corn – benefitting farmers, the environment, and consumers.
Inscripta Appoints Sri Kosaraju as President and CEO
Experienced growth-company leader joins as Inscripta embarks on next phase of commercial launch for its Onyx™ digital genome engineering platform
Inscripta, Inc., the digital genome engineering company, today announced the appointment of Sri Kosaraju as President and CEO. Kosaraju succeeds Kevin Ness.
Kosaraju currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics (NASDAQ: TXG) and is on the Board of the non-profit Testing for America. Prior to joining Inscripta, Kosaraju was President of Penumbra (NYSE: PEN), an innovative medical devices company, which he joined prior to their initial public offering as CFO in May 2015. During his tenure, Penumbra experienced rapid growth with revenues increasing from $125 million to $547 million. Earlier, Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets. While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. He holds a B.S. from the Massachusetts Institute of Technology.